世界のアルツハイマー病治療薬・診断市場予測...市場調査レポートについてご紹介

【英文タイトル】ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2014-2024
Opportunities for Leading Companies

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 The Alzheimer’s Disease Therapeutics and Diagnostics Market Overview
1.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2014-2024
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. Alzheimer’s Disease: An Introduction
2.1 Neurodegenerative Diseases
2.1.1 What is Alzheimer’s Disease?
2.1.2 What Causes Alzheimer’s Disease?
2.1.2.1 Alzheimer’s Disease: Type 3 Diabetes?
2.1.3 Management of Alzheimer’s Disease
2.1.4 The Socio-Economic Impact of Alzheimer’s Disease
2.1.5 Diagnosis of Alzheimer’s Disease

3. Alzheimer’s Disease Therapeutics and Diagnostics Market 2014-2024
3.1 Alzheimer’s Disease Therapeutics and Diagnostics Market, 2013
3.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
3.2.1 The Market Has Been Left Exposed to Intensified Generic Competition
3.2.2 Healthcare Costs for Alzheimer’s Disease Will Surpass All Other Medical Expenses
3.2.3 New Diagnostics and Drugs Regulatory Guidelines Will Lower the Barriers to Entry
3.3 Drivers and Restraints

4. The Alzheimer’s Disease Drugs Market, 2014-2024
4.1 Current Approaches and Unmet Needs in the Treatment of Alzheimer’s disease
4.2 The Alzheimer’s Disease Drugs Market, 2013
4.3 Changing Market Shares of the Leading Alzheimer’s Disease Drugs, 2014-2024
4.4 The Alzheimer’s Disease Drugs Market Forecast 2014-2024
4.5 Namenda
4.5.1 Namenda Sales Forecast, 2014-2024
4.6 Aricept
4.6.1 Aricept Sales Forecast, 2014-2024
4.7 Exelon
4.7.1 Exelon Sales Forecast, 2014-2024
4.8 Alzheimer’s Disease Drugs Pipeline, 2014
4.8.1 Recent High-Profile Failures of Clinical Trials for Alzheimer’s Disease Drug Candidates
4.8.1.1 Solanezumab (Eli Lilly)
4.8.1.2 LY-2886721 (Eli Lilly)
4.8.1.3 GSK2647544 (GSK)
4.8.1.4 Bapineuzumab (Elan/J&J/Pfizer)
4.8.1.5 Gammagard (Baxter)
4.9 FDA to Relax Rules for the Approval of Alzheimer’s Drugs
4.10 Will Novel Drug Development Strategies Prove Successful?
4.11 Promising Therapies in the Alzheimer’s Disease Drugs Pipeline, 2013
4.11.1 Solanezumab (Eli Lilly)
4.11.1.1Solanezumab Sales Forecast 2014-2024
4.11.2 Gantenerumab (Roche)
4.11.2.1The Gantenerumab Pipeline Forecast, 2014-2024
4.11.3 MK-8931 (Merck)
4.11.3.1 The MK-8931 Pipeline Forecast, 2014-2024
4.11.4 TTP488 (TransTechPharma)
4.11.5 LMTX (TauRx)
4.11.6 EVP-6124 (Forum Pharmaceuticals)
4.12 Deep Brain Stimulation (Functional Neuromodulation)
4.13 Leading Companies in the Alzheimer’s Disease Drugs Market, 2013
4.13.1 Pfizer, Inc
4.13.1.1Sales and Recent Performance Analysis, 2013
4.13.1.2 Pfizer: Aricept
4.13.1.3 Pfizer: R&D Capabilities and Alzheimer’s Disease Drug Candidates
4.13.2 Eisai
4.13.2.1 Sales and Recent Performance Analysis, 2013
4.13.2.2 Eisai: Aricept
4.13.2.3 Eisai: R&D Capabilities and Alzheimer’s Disease Drug Candidates
4.13.2.4 Collaboration with Biogen
4.13.2.5 Partnership with GE Healthcare for Diagnostic Development
4.13.3 Forest Laboratories (Acquired by Actavis)
4.13.3.1Acquisition by Actavis
4.13.3.2 Forest: Namenda
4.13.3.3 Namenda’s Sales and Recent Performance Analysis, 2013
4.13.4 Lundbeck A/S
4.13.4.1 Sales and Recent Performance Analysis, 2013
4.13.4.2 Lundbeck: R&D Capabilities
4.13.4.3 Lundbeck’s Alzheimer’s Disease Drug Pipeline
4.13.4.4 Lundbeck: Ebixa
4.13.5 Daiichi Sankyo
4.13.5.1 Financial Sales and Recent Performance, 2013
4.13.5.2 Daiichi Sankyo: Memary
4.13.6 Novartis AG
4.13.6.1 Sales and Recent Performance Analysis, 2013
4.13.6.2 Novartis: Exelon
4.13.6.3 eHealth Programme Delivering Innovation
4.13.6.4 Novartis: Alzheimer’s Disease Drug Pipeline
4.13.7 TauRx
4.13.7.1 Partnership with Bayer Schering Pharma AG
4.13.8Transtech Pharma
4.13.8.1TTP Translational Technology
4.13.8.2 TranstechPharma: Alzheimer’s Disease Pipeline Portfolio

5. The Alzheimer’s Disease Diagnostics Market, 2014-2024
5.1 There is Still a Strong Market Need for Effective Diagnosis
5.2 The Alzheimer’s Disease Diagnostics Market, 2013
5.3 Changing Market Shares of Leading Alzheimer’s Diagnostic Markets, 2014-2024
5.4 The Alzheimer’s Diagnostics Market, 2014-2024
5.5 New Criteria and Guidelines to Diagnose Alzheimer’s Disease
5.6 Biomarkers for Alzheimer’s Disease
5.6.1 Leading Companies Pursuing Novel Biomarker Development Strategies
5.7 Alzheimer’s Disease: Advances in Diagnostic Imaging Technologies
5.7.1 Structural Imaging
5.7.2 Functional Imaging
5.7.3 Molecular Imaging Technologies
5.7.3.1 Pittsburgh Compound B (PIB) (GE Healthcare)
5.7.3.2 Florbetapir F18 (18F-AV-45) (Eli Lilly)
5.7.3.3 Flutemetamol (GE Healthcare)
5.7.3.4 Florbetaben (Piramal Imaging)
5.8 Other Alzheimer’s Diagnostics in Development
5.8.1 CSF Proteins
5.8.2 Blood Based Biomarkers for Alzheimer’s Disease
5.8.3 Genetic Risk Profiling
5.8.4 Eye Tests
5.9 Leading Companies in the Alzheimer’s Disease Diagnostics Market, 2014
5.9.1 Eli Lilly
5.9.1.1 Recent Performance and Sales Analysis, 2013
5.9.1.2 Alzheimer’s Disease Research Effort
5.9.1.3 Solanezumab
5.9.1.4 Amyvid (Florbetapir F18)
5.9.1.5 Amyvid Receives Marketing Authorization from the European Commission
5.9.1.6 LY-2886721: Terminated Drug
5.9.1.7 N3pG-AB mAb:Phase I
5.9.1.8 Eli Lilly Acquires Novel Tau Tangle Diagnostic Programme
5.9.2 Amarantus BioScience Holdings, Inc.
5.9.2.1 Recent Performance and Sales Analysis, 2013
5.9.2.2 LymPro
5.9.2.3 Intellectual Property Acquisitions
5.9.3 Piramal Enterprises
5.9.3.1Piramal Imaging SA
5.9.3.2 U.S. and EMA Approval of Florbetaben
5.9.3.3 Manufacturing and Distribution Agreements
5.9.4 GE Healthcare
5.9.4.1 GE’s Commitment to Imaging Research in the Alzheimer’s Field
5.9.4.2 Regulatory Approval of Flutemetamol
5.9.4.3 Licensing Agreements for Flutemetamol
5.9.5 Navidea
5.9.5.1 NAV4694 (Fluorine-18)
5.9.5.2 Collaboration Agreements
5.9.5.3 NAV4694 Clinical Development
5.9.6 Diagenic
5.9.6.1 Organisational Restructuring

6. The Leading National Markets, 2014-2024
6.1 Regional Breakdown of the Global Alzheimer’s Disease Therapeutics and Diagnostic Market, 2013
6.1.1 The US and Europe Represent More than 70% of the Total Market
6.2 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Regional Forecast, 2014-2024
6.3 Changing Market Shares of Leading National Markets 2014-2024
6.4 The US Alzheimer’s Disease Therapeutics and Diagnostics Market, 2014-2024
6.4.1 One in Eight Over the Age of 65 has AD in the US
6.4.2 The US Will Remain the Largest Market Over the Forecast Period
6.5 The European Alzheimer’s Disease Therapeutics and Diagnostics Market, 2014-2024
6.5.1 The German Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.5.2 The French Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast,
2014-2024
6.5.3 The UK Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-
2024
6.5.4 The Spanish Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, #
2014-2024
6.5.5 The Italian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast,
2014-2024
6.5.6 The Rest of Europe Alzheimer’s Disease Therapeutics and Diagnostics Market
Forecast, 2014-2024
6.6 The Japanese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.7 The Chinese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.8 The Indian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.9 The Brazilian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.10 The Russian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.11 The Rest of the World Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024

7. Qualitative Analysis of the Alzheimer’s Disease Therapeutics and Diagnostics Market, 2014-2024
7.1 SWOT Analysis
7.2 Strengths
7.2.1 Alzheimer’s Disease is a High Profile Disease
7.2.2 Expanding Patient Population
7.2.3 Strong R&D Pipeline in Both Sectors of the Market
7.3 Weaknesses
7.3.1 Current Drugs Only Treat the Symptoms of Alzheimer’s Disease
7.3.2 Recent Failures of Promising Drug Candidates in Clinical Trials
7.3.3 Poor Macroeconomic Conditions in Key Regions of the Market
7.4. Opportunities
7.4.1 Regulations Seeking Improved Standards of Alzheimer’s Disease Drug Development
7.4.2 Neurodegenerative Diseases Have Strong R&D
7.4.3 Emerging Markets Will Help Drive the Market
7.4.4 Advances in Diagnostic Technologies Will Improve Drug Market Penetration
7.5 Threats
7.5.1 Patent Expiries Will Lead to Further Generic Competition
7.5.2 New AD Therapies Face Political, Commercial and Social Pressures
7.6 Porter’s Five Force Analysis
7.6.1 Rivalry Among Competitors
7.6.2 Threats of New Entrants
7.6.3 Powers of Suppliers
7.6.4 Bargaining Power of Buyers
7.6.5 Threat of Substitutes

8. Expert Opinions
8.1 Dr Simon Ridley, Head of Research, Alzheimer’s Research UK
8.1.1 Alzheimer’s Treatment in Late Stage Development
8.1.2 The Benefits of Alzheimer’s Diagnosis: A Future Prospect
8.1.3 Alzheimer’s and its Relationship with Other Diseases
8.1.4 Strategies to Incentivise Alzheimer’s Research and Investment
8.2 David Hanlon, Director of Business Development and Strategic Collaborations, Quanterix
8.2.1 Ultra Sensitive Automated Immunoassay Platform for Alzheimer’s
8.2.2 Alzheimer’s Disease Blood-based Biomarkers
8.2.3 Research Based Setting of the Simoa Technology
8.2.4 Quanterix: Alzheimer’s Partners and Collaborations
8.3 Elizabeth Edgerly, Ph.D., Chief Program Officer, The Alzheimer’s Association Northern California and Northern Nevada
8.3.1 Alzheimer’s Severe Under diagnosis
8.3.2 Novel Biomarkers: Critical for Alzheimer’s Diagnosis
8.3.3 Alzheimer’s Treatment Paradigm: Needs to be More Universally Effective
8.3.4 A Push to Improve the Success of Alzheimer’s Research
8.3.5 Alzheimer’s Treatment: The Greatest Challenge

9. Conclusions
9.1 Novel Diagnostic Technologies Will Emerge First and Then the Disease Modifying Drugs
9.2 Disease Modifying Drugs Will Transform the Declining Alzheimer’s Market
9.3 Demographics Will Help Drive the Market Over the Forecast Period
9.4 Medicines and Diagnostic Tests for Alzheimer’s Disease Hold Great Potential from 2014 to 2024


【レポート販売概要】

■ タイトル:世界のアルツハイマー病治療薬・診断市場予測
■ 英文:ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2014-2024
Opportunities for Leading Companies
■ 発行日:2014年8月
■ 調査会社:visiongain
■ 商品コード:VISG409044
■ 調査対象地域:グローバル
  • 圧力管理式掘削(MPD)サービス の世界市場:一定坑底圧法(CBHP)、マッドキャップ掘削(MCD)、DGD、RFCD技術
    The global managed pressure drilling services market exhibits a lucrative growth potential of >10% for the next five years. The growth of this market is propelled by the rise in concerns about safety & environment and the increasing capital expenditure in E&P operations being carried out across the globe. The market is further driven by factors such as increasing cost of traditional drilling opera …
  • 睡眠時ブラキシズム治療の世界市場予測
    IntroductionSleep bruxism or nocturnal tooth grinding is a medical condition indicated by the clenching or grinding of teeth during sleep. The global sleeping bruxism treatment market is estimated to be driven by the increasing prevalence of sleep bruxism, growth in child population, changing lifestyle, and rising prevalence of obstructive sleep apnea. Sleep bruxism is a sleep-related movement dis …
  • 関税監査の世界市場2017-2021
    About Customs Audit One of the key growth stimulators in the global customs audit market is the severe penalties imposed by authorities for trade-related transgressions. As smuggling and security concerns are increasing, customs professionals are making regulations stringent, propelling the growth of the market. Also, companies focus on enhancing supply chain efficiency, which has prompted them to …
  • サウジアラビアの医療市場動向(~2022)
    Saudi Arabian healthcare sector caters to a rapidly growing population, and the concurrent increase in health issues is boosting the sector to flourish. Saudi Arabia is continuously investing in healthcare related projects in Kingdoms like Riyadh, Makkah, Jeddah, etc. for developing advance healthcare system in these regions. Moreover, the government is blending in the regulatory framework to attr …
  • 生体材料(バイオマテリアル)の世界市場予測(~2021):材料種類別(金属、セラミック、ポリマー、天然)、用途別
    The biomaterials market is projected to reach USD 149.17 Billion by 2021 from an estimated USD 70.90 Billion in 2016, at a CAGR of 16.0%. The growth of the overall market can be attributed to increased funds & grants by government bodies worldwide, the growing implantable devices market, technological advancements, rising number of hip and knee replacement procedures, and high growth in geriatric …
  • 世界主要国のRSウイルス検査(医療機器)市場:サプライヤーシェア及び市場予測
    The report presents a detailed analysis of the Respiratory Syncytial Virus diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Respiratory Syncytial Virus definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments:      …
  • アプリケーションセキュリティの世界市場2019-2023
    About this market The vendors in the market are offering cloud-based application security solutions to leverage the growing demand. Cloud-based solutions are less expensive than on-premises solutions. They do not require the actual installation of hardware and software, as they are maintained at the vendor's data center from where they can be accessed by enterprises on a subscription basis. Thus, …
  • 包装用ロボットの世界市場2016-2020
    About Packaging Robots Packaging is a process of wrapping or covering a product to protect and preserve its inert quality from the risk of contamination or damage during its entire journey from the manufacturing site to the customer location. Good packaging promotes ease of transportation and storage. In addition, it shows essential information about the product. Thus packaging assumes a critical …
  • 顕微鏡検査の世界市場予測(~2022年):光学顕微鏡、電子顕微鏡、AFM、STM、NSOM
    “Microscopy market is projected to register a CAGR of 5.7%.”The microscopy market is expected to register a CAGR of 5.7% to reach USD 7.39 billion by 2022 from USD 5.60 billion in 2017. Market growth can be attributed to the rising government and corporate funding for R&D in microscopy, technological advancements in microscopes, and the rising focus on nanotechnology and regenerative medicine. Whe …
  • Google Acquisitions and Strategy
    While advertising remains a core offering and the largest component from a revenue perspective, Google is increasingly focused on innovation and product/application integration to develop new businesses and business models. In addition to their own resources, Google is relying upon an aggressive acquisition strategy to help them expand in different business directions including advertising (improv …
  • 世界の自動車V2X(Vehicle to Everything)通信市場:V2V、V2I、V2P、V2H、IN-V、ITS、Car-to-X
    Vehicle-to-Everything communications, which encapsulate a trully Connected Vehicle -able to communicate with other vehicles, traffic lights, toll gates, pedestrians, and even the owner’s home, is the automotive sector’s answer to safe, clean and ultimatelly autonomous/self-driving vehicles. In 2014, the V2X market is still in its infancy comprising only Vehicle-to-Vehicle (V2V) and Vehicle-to-Infr …
  • 自動車ヘッドガスケットの世界市場2015-2019
    About automotive head gaskets Head gaskets are a vital part of engines and perform the critical function of sealing the engine block to the cylinder head. They have undergone several changes in their design and material composition to cater to changing technological trends and adapt to evolving specifications. In internal combustion engines, a mixture of air and fuel is ignited by a spark plug, le …
  • Quicksilver Resources Inc.社の石油・ガス開発・生産動向及びコスト分析(2013年第4四半期)
    Quicksilver Resources Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2013 Summary Quicksilver Resources Inc. (Quicksilver) is an independent oil and gas company. The company carries out the acquisition, exploration, production and development of oil, natural gas liquids (NGL’s) and natural gas. Quicksilver focuses on onshore properties in the US and Canada. The compan …
  • ローグレードグリオーマ(神経膠腫):世界の臨床試験レビュー(2014年上半期)
    Low-Grade Glioma Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Low-Grade Glioma Global Clinical Trials Review, H1, 2014" provides data on the Low-Grade Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Low-Grade Glioma. It includes an overview of the trial numbers and their recruitment statu …
  • 水中スポーツ用品の世界市場2017-2021:水泳用品、水球用品、アクアビクス用品
    About In-The-Water Sports EquipmentIn-the-water sports equipment include gear and equipment for three types of sports — swimming, water polo, and water aerobics. The growth of this market can be attributed to the increasing interest for water tourism, including in-the-water sports activities. The sport is governed by the Fédération Internationale de Natation Amateur (FINA). Technavio’s analysts fo …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。